Chongqing Genrix Biopharmaceutical (688443.SH) Receives Clinical Trial Approval for GR2301 Injection

Stock News09-17

Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that it has received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration, granting approval for the clinical trial application of the company's investigational product GR2301 injection. According to the announcement, GR2301 injection is a recombinant fully human anti-IL-15 monoclonal antibody independently developed by the company. It functions by binding to human IL-15, blocking the binding of IL-15 with IL-15Rα and the IL-15&IL-15Rα complex with the IL-2Rβ&IL-2Rγ complex, thereby inhibiting the downstream JAK-STAT signaling pathway to achieve therapeutic effects for autoimmune diseases such as vitiligo caused by IL-15 expression dysregulation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181553731?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181553731","market":"us","top_or_hot":-1,"title":"Chongqing Genrix Biopharmaceutical (688443.SH) Receives Clinical Trial Approval for GR2301 Injection","media":"Stock News","content":"<p>Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that it has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration, granting approval for the clinical trial application of the company's investigational product GR2301 injection. According to the announcement, GR2301 injection is a recombinant fully human anti-IL-15 monoclonal antibody independently developed by the company. It functions by binding to human IL-15, blocking the binding of IL-15 with IL-15Rα and the IL-15&IL-15Rα complex with the IL-2Rβ&IL-2Rγ complex, thereby inhibiting the downstream JAK-STAT signaling pathway to achieve therapeutic effects for autoimmune diseases such as vitiligo caused by IL-15 expression dysregulation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Genrix Biopharmaceutical (688443.SH) Receives Clinical Trial Approval for GR2301 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Genrix Biopharmaceutical (688443.SH) Receives Clinical Trial Approval for GR2301 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-17 16:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that it has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration, granting approval for the clinical trial application of the company's investigational product GR2301 injection. According to the announcement, GR2301 injection is a recombinant fully human anti-IL-15 monoclonal antibody independently developed by the company. It functions by binding to human IL-15, blocking the binding of IL-15 with IL-15Rα and the IL-15&IL-15Rα complex with the IL-2Rβ&IL-2Rγ complex, thereby inhibiting the downstream JAK-STAT signaling pathway to achieve therapeutic effects for autoimmune diseases such as vitiligo caused by IL-15 expression dysregulation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1181553731","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181553731","pubTimestamp":1758099039,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that it has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration, granting approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688443":"智翔金泰","BK0239":"医药制造"},"translate_title":"重庆Genrix生物制药（688443.SH）GR2301注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688443":1},"content_text":"Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that it has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration, granting approval for the clinical trial application of the company's investigational product GR2301 injection. According to the announcement, GR2301 injection is a recombinant fully human anti-IL-15 monoclonal antibody independently developed by the company. It functions by binding to human IL-15, blocking the binding of IL-15 with IL-15Rα and the IL-15&IL-15Rα complex with the IL-2Rβ&IL-2Rγ complex, thereby inhibiting the downstream JAK-STAT signaling pathway to achieve therapeutic effects for autoimmune diseases such as vitiligo caused by IL-15 expression dysregulation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181553731","isCrawlerRequest":true}